What is Genetic Technologies Price-to-Free-Cash-Flow?
As of today (2024-04-27), Genetic Technologies's share price is $2.221.
Genetic Technologies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.40. Hence, Genetic Technologies's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Genetic Technologies's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Genetic Technologies's highest Price-to-Free-Cash-Flow Ratio was 24.00. The lowest was 0.00. And the median was 23.00.
GENE's Price-to-Free-Cash-Flow is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 26.29 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 11.40% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 22.40% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 28.50% per year.
During the past 13 years, Genetic Technologies's highest 3-Year average Free Cash Flow per Share Growth Rate was 82.90% per year. The lowest was -97.70% per year. And the median was 18.60% per year.
Genetic Technologies Price-to-Free-Cash-Flow Historical Data
The historical data trend for Genetic Technologies's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Genetic Technologies's Price-to-Free-Cash-Flow
For the Diagnostics & Research subindustry, Genetic Technologies's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Technologies's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Genetic Technologies's Price-to-Free-Cash-Flow falls into.
Genetic Technologies's Share Price of today is $2.221. Genetic Technologies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.40.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Genetic Technologies Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Genetic Technologies's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Genetic Technologies (Genetic Technologies) Business Description
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GENE has been successfully added to your 